Figure 2
From: Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors
MAP4K4 inhibitors (GNE-495 and PF06260933) selectively targeted radioresistant cells. (A) Effects of PF06260933 and GNE-495 on MAP4K4 kinase activities. (B) Western blot of MAP4K4 in SR cells treated with PF06260933 or GNE-495. MAP4K4 protein levels are expressed as fold changes versus untreated cells (0 µM). Cytotoxic effects of (C) PF06260933 and (D) GNE-495 on parental (SK-BR-3 and MCF-7) and radioresistant (SR and MR) cells. Cells were treated with PF06260933 or GNE-495 for 48 h and cell viabilities were assessed using the sulforhodamine B (SRB) assay. Results are presented as means ± SDs, ** indicates P values of < 0.01 versus untreated cells.
